Skip to main content

lopinavir/ritonavir (Kaletra®)

 

Status: Medicine does not meet criteria for AWMSG assessment

Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information.

Medicine details

Medicine name lopinavir/ritonavir (Kaletra®)
Formulation 200 mg/50 mg film-coated tablet
Reference number 189
Indication

Treatment of HIV-1 infected adults and children above the age of 2 years, in combination with other antiretroviral agents

Company AbbVie Ltd
BNF chapter Infections
Submission type N/A
Status Medicine does not meet criteria for AWMSG assessment
Date of issue 19/09/2006
Follow AWTTC: